Intec Pharma Ltd

Intec Pharma — Merger or Acquisition (March 2021)

24 slides from Intec Pharma's merger presentation, Mar 15, 2021

  1. Slide 1: Project Dillion Investor Presentation

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Project Dillion Investor Presentation

  2. Slide 2: Forward Looking Statements

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Forward Looking Statements This presentation contains forward - looking statements with the meaning of the Private Securities Litigation Reform Act. These in clude statements regarding management’s expectations, beliefs and intentions regarding, among ot

  3. Slide 3: Intec Pharma announces merger with Decoy Biosystems

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Intec Pharma / Decoy Biosystems 2021 Intec Pharma announces merger with Decoy Biosystems 3 • Entry into exciting area of immuno - oncology • Continues pursuit of advancing new technologies • Potential value creating opportunity for shareholders • Leverag

  4. Slide 4: Decoy Investment Thesis

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Decoy Investment Thesis • Immunology - based anti - tumor and anti - viral platform with IND filing anticipated 2H ’21 • Pre - clinical data demonstrate Decoy safely primes innate and adaptive immune pathways • Technology active against multiple solid tu

  5. Slide 5: Immune System Well-Equipped to Prevent and Eliminate Tumors

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Immune System Well - Equipped to Prevent and Eliminate Tumors Checkpoint inhibitors (CPI) have revolutionized the treatment of oncology (immuno - oncology IO) Successes of Existing CPI • Broad & deep responses in multiple tumor settings with cures of adv

  6. Slide 6: Decoy Technology Activates Innate and Adaptive Pathways

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Decoy Technology Activates Innate and Adaptive Pathways • Significant advances will only be possible if we can safely activate both innate & adaptive anti - tumor immune pathways • Decoy therapy safely primes both pathways after short exposure • Potentia

  7. Slide 7: Harnessing Immune Activators in Bacteria

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Harnessing Immune Activators in Bacteria Bacteria contain multiple immune system stimulating “danger signals” – Toll - Like Receptors (TLR) agonists – NOD - Like Receptors (NLR) agonists – Stimulator of Interferon Genes (STING) Bacterial danger signals a

  8. Slide 8: Decoy's Innovation

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Decoy’s Innovation Innate and adaptive immunology mechanisms established since the 1990’s suggested a new path – The most potent and broadly acting bacterial danger signal is lipopolysaccharide (LPS) or endotoxin – LPS is the major (75%) component of the

  9. Slide 9: Decoy Technology

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Decoy Technology Briefly tricking the body into thinking an infection is present • Start with a single, pure strain of non - pathogenic, Gram - negative bacteria • Reduce LPS - endotoxin level by ~90% • Kill the bacteria and stabilize so they remain inta

  10. Slide 10: Decoy Pre-Clinical Assessments

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Decoy Pre - Clinical Assessments Decoy bacteria in vivo – Significant anti - tumor and anti - viral activity as a single agent – Synergistic induction of innate and adaptive immune pathways in tumors (cold to hot) – Anti - tumor synergy with anti - PD -

  11. Slide 11: In Vitro Data: Decoy Bacteria Induce Human Immune Cells to Secrete Cytokines

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. In Vitro Data: Decoy Bacteria Induce Human Immune Cells to Secrete Anti - Tumor Cytokines and Chemokines 11 *Decoy bacteria tested at doses therapeutically relevant for in vivo models **From one experiment Secretion by Human PBMCs* In Vitro Untreated Bac

  12. Slide 12: Single Agent Decoy Extends Survival in Metastatic Pancreatic Carcinoma

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Single Agent Decoy Extends Survival of Mice with Metastatic Mouse Pancreatic Carcinoma 12 0 10 20 30 40 50 60 70 80 90 0 20 40 60 80 100 Days Post Tumor Cell Inoculation (Treatment Started on Day 5 With 7 Mice/Group) P e r c e n t S u r v i v a l No Trea

  13. Slide 13: Single Agent Decoy Inhibits Metastasis in Orthotopic Colorectal Carcinoma

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Single Agent Decoy Inhibits Metastasis and Extends Survival of Mice with Orthotopic Mouse Colorectal Carcinoma 13 0 7 14 21 28 35 42 49 56 63 70 77 84 91 98 105112119 0 10 20 30 40 50 60 70 80 90 100 Days After Tumor Fragment Implant (Treatment Started o

  14. Slide 14: Decoy Synergizes with Anti-PD-1 to Regress Mouse HCC

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Decoy Synergizes with Anti - PD - 1 Checkpoint Therapy to Safely Regress Established Mouse Hepatocellular Carcinoma (HCC) 14 Decoy + Anti - PD - 1 6/6 CR (5/6 durable at Day 91) (6 mice per group) Anti - PD - 1 1/6 CR Decoy 2/6 CR 0 500 1,000 1,500 2,000

  15. Slide 15: Synergistic Full Regression of Murine HCC Exhibits Wide Therapeutic Index

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Synergistic Full Regression of Murine HCC by Decoy + Anti - PD - 1 Exhibits a Very Wide Therapeutic Index (≥33 - fold) All Decoy - treated groups received the same standard regimen of mouse anti - PD - 1 15 0 200 400 600 800 1,000 7 14 21 28 35 42 49 56

  16. Slide 16: Cured Mice Re-Challenged Reject Tumors (Immunological Memory)

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Mice Cured by Decoy + Anti - PD - 1 and Re - Challenged with Fresh HCC Tumor Cells Reject the Tumors (Immunological Memory) Eleven Cured Mice were Re - Challenged with Fresh HCC Tumor Cells on Day 91 on the Opposite Flank from the First Challenge Six Naï

  17. Slide 17: Decoy Produces Similar Results in Multiple Mouse Models

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Decoy Produces Similar Results in Multiple Mouse Models 17 0 1,000 2,000 3,000 4,000 5,000 13 20 27 34 41 48 55 62 69 76 Decoy Control LDC/no regressions Decoy + LDC 6/6 full regressions 0 500 1,000 1,500 2,000 13 20 27 34 41 48 55 62 69 76 83 90 97 104

  18. Slide 18: Target Indications Include World's Deadliest Cancers

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Target Indications Include 6 of the World’s 12 Deadliest Cancers 18 Unmet Need - % 5 Year Survival * 20% 30% 40% 50% 60% 70% 80% 90% 10% Competitive Environment Ongoing Phase 3 Studies ** 20 200 100 Patients do worse Patients do better Pancreas 115K inci

  19. Slide 19: Decoy Technology Platform: Potential Utility as Anti-viral Therapy

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Decoy Technology Platform Potential utility as anti - viral therapy Other Infections 19 HBV Oncology Cancer immunotherapy principles (opportunities and challenges) also apply to chronic viral infections Long - standing scientific rationale for use of TLR

  20. Slide 20: Decoy Clinical Development Plan

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. 2021 2022 2023 2024 2025 Q1/2 Q3/4 Q1/2 Q3/4 Q1/2 Q3/4 Q1/2 Q3/4 Q1/2 Q3/4 Dose Escalation Expansion (~2 tumors) Ph1b Combination Checkpoint / Targeted Abs / Chemo Decoy Clinical Development Plan 20 Preparations Underway for IND Filing (expected 2H 2021)

  21. Slide 21: Experienced Board of Directors

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Experienced Board of Directors 21 Roger J. Pomerantz, M.D. Chairman elect Michael J. Newman, Ph.D. Founder, CSO, Director Jeffrey Meckler CEO, Director Anthony J. Maddaluna Director W. Brad Hayes Director Brian O’Callaghan Director Hila Karah Director Ho

  22. Slide 22: Favorable Risk/Opportunity Profile

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Favorable Risk/Opportunity Profile 22 Attribute Milestones Intellectual Property • 31 issued or granted patents, including composition of matter (plus applications) In Vivo Activity • Single agent activity and combination - based tumor eradications in mu

  23. Slide 23: Additional Information and Where You Can Find It

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Additional Information and Where You Can Find It This communication relates to the proposed domestication merger of Intec and the merger of Intec and Decoy. In connection wit h t he proposed domestication merger and merger, Intec will file a Registration

  24. Slide 24: Thank you.

    TEMPLATE NOT FINAL. DO NOT CIRCULATE FOR USE. Thank you. 24

Intec Pharma — Merger or Acquisition (March 2021) on 6ix